Missed NVDA?
Don’t Miss the Next One.
Join 5,000+ investors using Ticker Nerd’s Market Radar to stay ahead of major market moves, analyst upgrades, and trending opportunities — for free.
EYEN Stock Forecast 2025-2026
$6.44
Current Price
$32.87M
Market Cap
Buy 0
Hold 1
Sell 0
Wall St Analyst Ratings
Distance to EYEN Price Targets
N/A
To High Target of $N/A
N/A
To Median Target of $N/A
N/A
To Low Target of $N/A
EYEN Price Momentum
-0.6%
1 Week Change
-23.2%
1 Month Change
-83.5%
1 Year Change
-44.9%
Year-to-Date Change
-84.5%
From 52W High of $41.44
+657.6%
From 52W Low of $0.85
📊 TOP ANALYST CALLS
Did EYEN Make This Month's Elite Buy List?
We don't follow just any analyst — only the top 3% with a proven track record make our cut. See if Eyenovia is one of their latest high-conviction picks.
Latest EYEN Stock Price Targets & Analyst Predictions
EYEN has shown a year-to-date change of -44.9% and a 1-year change of -83.5%, reflecting downward momentum over the past year. Comprehensive analyst forecasts are currently unavailable for EYEN. Please refer to the price chart above for recent performance and trends.
Please note that analyst price targets are forward-looking estimates subject to substantial market, economic, and company-specific risks. Past performance does not guarantee future results, and actual stock performance may materially differ from these projections. Investors should conduct their own due diligence and consider their investment objectives and risk tolerance before making investment decisions.
EYEN Analyst Ratings
0
Buy
1
Hold
0
Sell
EYEN Price Target Range
Low
N/A
Average
N/A
High
N/A
Current: $6.44
Latest EYEN Stock Forecasts by Analyst
These are the latest 20 analyst ratings and price targets for EYEN.
| Date | Firm | Analyst | Rating | Change | Price Target |
|---|---|---|---|---|---|
| Mar 21, 2025 | HC Wainwright & Co. | Matthew Caufield | Neutral | Reiterates | $2.00 |
| Feb 6, 2025 | HC Wainwright & Co. | Matthew Caufield | Neutral | Reiterates | $2.00 |
| Nov 18, 2024 | Ladenburg Thalmann | Matthew Kaplan | Neutral | Downgrade | $N/A |
| Nov 18, 2024 | HC Wainwright & Co. | Matthew Caufield | Neutral | Downgrade | $2.00 |
| Nov 15, 2024 | William Blair | Tim Lugo | Market Perform | Downgrade | $N/A |
| Nov 15, 2024 | Brookline Capital | Kemp Dolliver | Hold | Downgrade | $N/A |
| Nov 13, 2024 | HC Wainwright & Co. | Matthew Caufield | Buy | Reiterates | $12.00 |
| Aug 13, 2024 | HC Wainwright & Co. | Matthew Caufield | Buy | Reiterates | $12.00 |
| Jul 24, 2024 | HC Wainwright & Co. | Matthew Caufield | Buy | Reiterates | $12.00 |
| May 16, 2024 | HC Wainwright & Co. | Matthew Caufield | Buy | Reiterates | $12.00 |
| Mar 19, 2024 | HC Wainwright & Co. | Matthew Caufield | Buy | Reiterates | $12.00 |
| Mar 6, 2024 | HC Wainwright & Co. | Matthew Caufield | Buy | Reiterates | $12.00 |
| Nov 14, 2023 | HC Wainwright & Co. | Matthew Caufield | Buy | Reiterates | $12.00 |
| Nov 1, 2023 | William Blair | Tim Lugo | Outperform | Initiates | $N/A |
| Oct 17, 2023 | Brookline Capital | Kemp Dolliver | Buy | Initiates | $8.00 |
| Aug 18, 2023 | HC Wainwright & Co. | Matthew Caufield | Buy | Reiterates | $12.00 |
| Aug 11, 2023 | HC Wainwright & Co. | Matthew Caufield | Buy | Reiterates | $12.00 |
| May 12, 2023 | HC Wainwright & Co. | Matthew Caufield | Buy | Reiterates | $12.00 |
| Apr 19, 2023 | HC Wainwright & Co. | Matthew Caufield | Buy | Reiterates | $12.00 |
| Apr 3, 2023 | HC Wainwright & Co. | Matthew Caufield | Buy | Reiterates | $12.00 |
Eyenovia Inc. (EYEN) Competitors
The following stocks are similar to Eyenovia based on their market capitalization and industry sector. These similar stocks potentially provide investors with alternative investment opportunities within the same market segment.
Eyenovia Inc. (EYEN) Financial Data
Eyenovia Inc. has a market capitalization of $32.87M with a P/E ratio of -0.1x. The company generates $57,336 in trailing twelve-month revenue with a -6,749.5% profit margin.
Revenue growth is -100.0% quarter-over-quarter, while maintaining an operating margin of -82,555.5% and return on equity of +380.4%.
Valuation Metrics
Market Cap
$32.87M
Enterprise Value
$41.99M
P/E Ratio
-0.1x
PEG Ratio
0.0x
Price/Sales
573.3x
Growth & Margins
Revenue Growth (YoY)
-100.0%
Gross Margin
N/A
Operating Margin
-82,555.5%
Net Margin
-6,749.5%
EPS Growth
-100.0%
Financial Health
Cash/Price Ratio
N/A
Current Ratio
0.9x
Debt/Equity
0.2x
ROE
+380.4%
ROA
-1,358.3%
💡 SKIP THE NOISE
97% of Analyst Ratings Go Nowhere
We filter thousands of calls to find the few that actually matter. Get the top analyst buy ratings — tracked and updated every Monday and Thursday.
Eyenovia Inc. (EYEN) Business Model
About Eyenovia Inc.
What They Do
Develops advanced therapies for eye conditions.
Business Model
Eyenovia Inc. operates on a biotechnology model focused on developing microdose treatments for eye-related conditions. The company generates revenue by creating innovative ocular therapies that improve drug delivery precision and safety, particularly for chronic eye diseases like presbyopia and myopia.
Additional Information
Based in New York, Eyenovia is recognized for its pioneering microdosing technology, which enhances treatment efficacy while reducing side effects. The company engages in strategic collaborations and ongoing research, aiming to transform traditional eye care into more effective and patient-friendly solutions.
Company Information
Sector
Healthcare
Industry
Biotechnology
Employees
13
CEO
Mr. Michael M. Rowe
Country
United States
IPO Year
2018
Website
www.eyenovia.comEyenovia Inc. (EYEN) Latest News & Analysis
Latest News
Eyenovia Surges on Crypto Announcement
4 months ago
Quick Summary
Eyenovia shares doubled after the company announced a $50 million investment agreement and plans for a hyperliquid cryptocurrency treasury reserve strategy.
Why It Matters
Eyenovia's share surge reflects investor optimism from the $50 million investment and potential growth from the cryptocurrency treasury strategy, signaling increased confidence in the company's future.
Source: Market Watch
Market Sentiment:
Positive
Quick Summary
Eyenovia, Inc. (NASDAQ: EYEN) announced a $50 million PIPE financing with institutional investors and appointed Hyunsu Jung as Chief Investment Officer and Board Member.
Why It Matters
Eyenovia's $50 million PIPE financing signifies strong institutional interest, enhancing liquidity and financial stability, while its unique treasury strategy may attract attention and boost stock value.
Source: GlobeNewsWire
Market Sentiment:
Neutral
Quick Summary
EYEN is hiring a significant figure from Hyperliquid to assist with its HYPE Treasury Strategy.
Why It Matters
The appointment of a major thought leader suggests EYEN is strengthening its treasury strategy, potentially enhancing operational efficiency and investor confidence in its financial management.
Source: GlobeNewsWire
Market Sentiment:
Neutral
Quick Summary
Chardan expands into the digital asset sector, advising on transactions linking traditional markets with blockchain. They acted as placement agent in Eyenovia's $50M PIPE financing for HYPE Tokens.
Why It Matters
Chardan's expansion into digital assets signals growing institutional interest in cryptocurrencies, potentially driving market adoption and investment opportunities in this sector.
Source: PRNewsWire
Market Sentiment:
Neutral
Quick Summary
Eyenovia and Betaliq are in negotiations for a binding merger agreement, following their previously signed Letter of Intent.
Why It Matters
Ongoing merger negotiations between Eyenovia and Betaliq could impact stock prices, investor sentiment, and future growth potential for both companies.
Source: GlobeNewsWire
Market Sentiment:
Neutral
Quick Summary
A regulatory submission for marketing approval of the Optejet UFD is anticipated in Q4 2025.
Why It Matters
Regulatory approval for the Optejet UFD could significantly impact the company's revenue potential and market position, influencing stock performance and investor sentiment.
Source: GlobeNewsWire
Market Sentiment:
Neutral
Frequently Asked Questions About EYEN Stock
What is Eyenovia Inc.'s (EYEN) stock forecast for 2026?
Analyst forecasts for Eyenovia Inc. (EYEN) are not currently available. The stock is trading at $6.44.
Is EYEN stock a good investment in 2026?
According to current analyst ratings, EYEN has 0 Buy ratings, 1 Hold ratings, and 0 Sell ratings. The stock is currently trading at $6.44. Always conduct your own research and consider your investment goals before making investment decisions.
What is the long-term price prediction for EYEN stock?
Price predictions from Wall Street analysts for EYEN are not currently available. The stock is trading at $6.44.
What is Eyenovia Inc.'s business model?
Eyenovia Inc. operates on a biotechnology model focused on developing microdose treatments for eye-related conditions. The company generates revenue by creating innovative ocular therapies that improve drug delivery precision and safety, particularly for chronic eye diseases like presbyopia and myopia.
What is the highest forecasted price for EYEN Eyenovia Inc.?
Price targets from Wall Street analysts for EYEN are not currently available. The stock is trading at $6.44.
What is the lowest forecasted price for EYEN Eyenovia Inc.?
Price targets from Wall Street analysts for EYEN are not currently available. The stock is trading at $6.44.
What is the overall EYEN consensus from analysts for Eyenovia Inc.?
The overall analyst consensus for EYEN is neutral. Out of 6 Wall Street analysts, 0 rate it as Buy, 1 as Hold, and 0 as Sell.
How accurate are EYEN stock price projections?
Stock price projections, including those for Eyenovia Inc., are based on various factors including financial models, market conditions, and analyst forecasts. While these predictions provide valuable insights, they should be considered alongside your own research and risk tolerance.
Important Disclaimer
The information provided by Ticker Nerd is for educational and informational purposes only. It should not be considered financial or investment advice. Past performance is not indicative of future results. Always conduct your own research and consult with a qualified financial advisor before making any investment decisions. Analyst ratings and price forecasts are sourced from Wall St analysts and other experts. These projections are speculative and do not guarantee future stock performance.
Last updated: November 9, 2025 11:55 AM UTC